Vaccine composition

Patent metadata

Field	Value
Publication number	US-10076491-B2
Application number	US-201414166965-A
Country	US
Kind code	B2
Filing date	Jan 29, 2014
Priority date	Feb 5, 2013
Publication date	Sep 18, 2018
Grant date	Sep 18, 2018

Abstract

The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter.

First claim

What is claimed is:

1. A method for inducing cellular immunity in a subject, comprising transdermally administering, to intact skin or under mildly irritating conditions, an immunogenic composition comprising:
an antigen,
at least one first cellular immunity induction promoter selected from the group consisting of a cyclooxygenase inhibitor, a prostaglandin receptor antagonist, a prostaglandin receptor agonist, a TSLP production inhibitor, an adenylate cyclase inhibitor, an omega-3 fatty acid, a PPAR agonist, a dopamine receptor antagonist, a dopamine receptor agonist, a histamine receptor agonist, a histamine receptor antagonist, a serotonin receptor agonist, a serotonin receptor antagonist, a vasopressin receptor antagonist, a vasopressin receptor agonist, a muscarine receptor antagonist, a muscarine receptor agonist, an adrenergic receptor antagonist, an adrenergic receptor agonist, an angiotensin receptor agonist, a GABA receptor agonist, a thrombin receptor antagonist, a thrombin receptor agonist, an opioid receptor agonist, an ADP receptor agonist, a leukotriene receptor antagonist, a leukotriene receptor agonist, a melatonin receptor agonist, a somatostatin receptor agonist, a cannabinoid receptor agonist, a sphingosine-1 phosphate receptor agonist, a metabotropic glutamate receptor agonist, a phospholipase A2 inhibitor, a TGF-β production inhibitor, and a Th2 cytokine inhibitor, and
a TLR ligand other than a TLR9 ligand.

2. The method according to claim 1 , wherein the composition is administered to the skin under a mildly irritating condition.

3. The method according to claim 2 , wherein the mildly irritating condition is a condition under which transepidermal water loss (TEWL) in a model animal for skin irritation evaluation before the administration of the composition is 50 g/hm 2 or less.

4. The method according to claim 2 , wherein the mildly irritating condition is a condition under which the cutaneous TSLP level in a model animal for skin irritation evaluation at completion of the administration of the composition is 10000 pg/mg protein or less.

5. The method according to claim 1 , wherein the method is for the treatment of a cancer.

6. The method according to claim 1 , wherein the method is for the treatment of a viral disease.

7. The method according to claim 1 , wherein the TLR ligand is a TLR4 ligand.

8. The method according to claim 7 , wherein the TLR4 ligand is a lipopolysaccharide (LPS) derived from bacteria or plants.

9. The method according to claim 8 , wherein the TLR4 ligand is a lipopolysaccharide (LPS) derived from Pantoea genus.

10. The method according to claim 1 , wherein the TLR ligand is a TLR7 and/or TLR8 ligand.

11. The method according to claim 10 , wherein the TLR7 and/or TLR8 ligand is imiquimod.

12. The method according to claim 1 , wherein the first cellular immunity induction promoter is a cyclooxygenase inhibitor.

13. The method according to claim 12 , wherein the cyclooxygenase inhibitor is selected from etodolac, loxoprofen, indomethacin, aspirin, diclofenac, ketoprofen, celecoxib, valdecoxib, and derivatives thereof, and pharmacologically acceptable salts thereof.

14. The method according to claim 12 , wherein the cyclooxygenase inhibitor is loxoprofen.

15. The method according to claim 11 , wherein the cyclooxygenase inhibitor is loxoprofen.

Assignees

• Nitto Denko Corp

Inventors

• Asari Daisuke
• Okubo Katsuyuki
• Shishido takuya
• Okazaki Arimichi
• Maeda Yoshiki
• Matsushita Kyohei
• Li Wenjing
• Hori Mitsuhiko
• Sugiyama Haruo

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title